JP4652325B2 - 虚血性疾患用の低酸素状態誘導可能ｖｅｇｆプラスミド - Google Patents

虚血性疾患用の低酸素状態誘導可能ｖｅｇｆプラスミド Download PDF

Info

Publication number
JP4652325B2
JP4652325B2 JP2006503825A JP2006503825A JP4652325B2 JP 4652325 B2 JP4652325 B2 JP 4652325B2 JP 2006503825 A JP2006503825 A JP 2006503825A JP 2006503825 A JP2006503825 A JP 2006503825A JP 4652325 B2 JP4652325 B2 JP 4652325B2
Authority
JP
Japan
Prior art keywords
prtp801
seq
plasmid
vegf
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006503825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518604A (ja
JP2006518604A5 (enExample
Inventor
リー，ミンフュン
キム，サン・ワン
Original Assignee
ユニバーシティ オブ ユタ リサーチ ファウンデイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ユタ リサーチ ファウンデイション filed Critical ユニバーシティ オブ ユタ リサーチ ファウンデイション
Publication of JP2006518604A publication Critical patent/JP2006518604A/ja
Publication of JP2006518604A5 publication Critical patent/JP2006518604A5/ja
Application granted granted Critical
Publication of JP4652325B2 publication Critical patent/JP4652325B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006503825A 2003-02-21 2004-02-23 虚血性疾患用の低酸素状態誘導可能ｖｅｇｆプラスミド Expired - Fee Related JP4652325B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44896103P 2003-02-21 2003-02-21
PCT/US2004/005372 WO2004076633A2 (en) 2003-02-21 2004-02-23 Hypoxia inducible vegf plasmid for ischemic disease

Publications (3)

Publication Number Publication Date
JP2006518604A JP2006518604A (ja) 2006-08-17
JP2006518604A5 JP2006518604A5 (enExample) 2007-04-05
JP4652325B2 true JP4652325B2 (ja) 2011-03-16

Family

ID=32927484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503825A Expired - Fee Related JP4652325B2 (ja) 2003-02-21 2004-02-23 虚血性疾患用の低酸素状態誘導可能ｖｅｇｆプラスミド

Country Status (9)

Country Link
US (2) US7638322B2 (enExample)
EP (1) EP1594549B1 (enExample)
JP (1) JP4652325B2 (enExample)
KR (1) KR101077689B1 (enExample)
AT (1) ATE456380T1 (enExample)
CA (1) CA2516727C (enExample)
DE (1) DE602004025328D1 (enExample)
ES (1) ES2339113T3 (enExample)
WO (1) WO2004076633A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101094617B1 (ko) 2004-08-16 2011-12-15 사일런스 테라퓨틱스 아게 알티피801 억제제의 치료적 용도
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
GB2450840B (en) * 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
JP2010518880A (ja) 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１のインヒビター及びその疾患の治療における使用
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6548633B1 (en) * 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides

Also Published As

Publication number Publication date
WO2004076633A2 (en) 2004-09-10
DE602004025328D1 (de) 2010-03-18
US7638322B2 (en) 2009-12-29
KR20050103302A (ko) 2005-10-28
KR101077689B1 (ko) 2011-10-27
US20110015257A1 (en) 2011-01-20
JP2006518604A (ja) 2006-08-17
ATE456380T1 (de) 2010-02-15
ES2339113T3 (es) 2010-05-17
US20070149467A1 (en) 2007-06-28
US7998941B2 (en) 2011-08-16
EP1594549A4 (en) 2008-01-23
CA2516727C (en) 2014-02-04
WO2004076633A3 (en) 2005-06-02
CA2516727A1 (en) 2004-09-10
EP1594549B1 (en) 2010-01-27
EP1594549A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
US8859747B2 (en) Promoters exhibiting endothelial cell specificity and methods of using same
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
JPH11506302A (ja) 組織特異的低酸素で調節される治療用構築物
US7998941B2 (en) Hypoxia inducible VEGF plasmid for ischemic disease
US7067649B2 (en) Promoters exhibiting endothelial cell specificity and methods of using same
CN113564187A (zh) 基于aav的抗血管生成基因递送系统及其用途
CN113480615B (zh) 高视网膜亲和性的新型腺相关病毒衣壳蛋白及其应用
CN113563430B (zh) 用于治疗眼部疾病的基因递送系统及其应用
CN113584043B (zh) 用于治疗视网膜疾病和癌症的转基因表达盒
KR20080036015A (ko) 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법
EP2186530B1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
JP2003189887A (ja) 筋肉細胞での発現を制御するためのキメラプロモーター
US7604798B2 (en) Methods and compositions for importing nucleic acids into cell nuclei
AU2007212260A1 (en) Method for treating peripheral arterial disease with zinc finger proteins
IL322548A (en) AAV PIGGYBAC transposon polynucleotide compositions and methods of using them
AU2002224002C1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
HK1143082B (en) Promoters exhibiting endothelial cell specificity and methods of using same
AU2002224002A1 (en) Promoters exhibiting endothelial cell specificity and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101215

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees